|
|
|
2016, Volume 32, Number 3, Page(s) 141-147
|
|
|
DOI: 10.5146/tjpath.2015.01352 |
GLUT-1 Expression in Proliferative Endometrium, Endometrial Hyperplasia, Endometrial Adenocarcinoma and the Relationship Between GLUT-1 Expression and Prognostic Parameters in Endometrial Adenocarcinoma |
Tuba CANPOLAT1, Canan ERSÖZ1, Aysun UĞUZ1, Mehmet Ali VARDAR2, Aytekin ALTINTAŞ2 |
1Department of Pathology, Cukurova University School of Medicine, ADANA, TURKEY
2Department of Obstetrics and Gynecology, Cukurova University School of Medicine, ADANA, TURKEY |
Keywords:
GLUT-1, Prognosis, Endometrial hyperplasia, Endometrioid adenocarcinoma |
Objective: Malignant cells show increased glucose uptake in in vitro and in vivo studies. This uptake is mediated by glucose transporter proteins.
GLUT-1 is the most common transporter protein, and its expression is reported to be increase in many human cancers. The aim of this study
is to determine the GLUT-1 overexpression in benign, hyperplastic, and malignant endometrial tissues, to evaluate the usefulness of GLUT-1
expression in endometrial hyperplasia, and to determine its role in the neoplastic progression to endometrioid type adenocarcinoma. We also
aimed to analyze prognostic clinical parameters, predict prognosis, and survival.
Material and Method: We examined immunohistochemical expression of GLUT-1 in 91 cases of endometrial hyperplasia, 100 cases of
endometrioid type adenocarcinoma, and 10 proliferative endometrial tissues. The percentage of positive cells and staining intensity were assessed
in a semi quantitative fashion and scored (1+ to 3+).
Results: GLUT-1 immunoreactivity was not present in proliferative endometrium. Twenty-nine (31.9%) of 91 endometrial hyperplasia cases
showed positive immunoreactivity, of which only six were cases of hyperplasia without atypia while 23 of them were cases with atypia. We
found GLUT-1 positivity of 95% in endometrioid type adenocarcinoma. GLUT-1 overexpression was not significantly correlated with any of
the clinicopathological parameters except histological grade in endometrioid adenocarcinoma; the survival was not found to be correlated with
GLUT-1 expression.
Conclusion: GLUT-1 immunostaining may be useful in distinguishing hyperplasia without atypia from hyperplasia with atypia; GLUT-1
overexpression is a consistent feature of endometrioid adenocarcinoma. A correlation between GLUT -1 expression and tumor grade has been
found, although other prognostic parameters and survival has no meaningful correlation.
|
|
|
|
|
